Core Viewpoint - Inspira Technologies has secured a significant patent for its Convertible Dual Lumen Cannula device in Japan, enhancing its market position in the medical device sector and supporting future commercialization efforts [1][2]. Group 1: Patent and Market Position - The Japan Patent Office granted Patent No. 7777598, providing Inspira exclusive commercial rights for the Dual Lumen Cannula technology in Japan until 2041 [2]. - This patent complements an existing U.S. Patent granted in 2023, creating a protective barrier across two major healthcare markets [2]. - The patented technology allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly, which may reduce infection risks and procedural complications compared to traditional solutions [3]. Group 2: Product and Strategic Implications - The Convertible Dual Lumen Cannula is designed to be a high-value disposable product, potentially enhancing patient safety and procedural efficiency while being more affordable than traditional dual-lumen cannulas [4]. - The company is positioned to benefit from both its respiratory support platforms and future disposable revenue streams due to the proprietary protection in the U.S. and Japan [4]. - Inspira Technologies is advancing its product offerings, including the INSPIRA™ ART100 system for cardiopulmonary bypass and the next-generation INSPIRA ART500 system, which aims to deliver oxygenation while patients remain awake [5].

Core Insights - Inspira Technologies has been granted Patent No. 7777598 by the Japan Patent Office for its Convertible Dual Lumen Cannula device, securing exclusive rights in Japan until 2041, complementing its existing U.S. patent [1][2] - The patented technology allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly after insertion, potentially reducing infection risks and procedural complications compared to traditional solutions [3][4] - The company aims to commercialize the cannula as a high-value disposable product, enhancing patient safety and procedural efficiency while addressing the high manufacturing costs of traditional dual lumen cannulas [4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its INSPIRA™ ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake, and advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [5] - With a growing IP portfolio and strategic operational streamlining, Inspira Technologies is positioned as an attractive player in the life-support and MedTech landscape, aligning with industry trends such as consolidation and potential strategic partnerships [5]